Azizi Mehdi, Valizadeh Hadi, Shahgolzari Mehdi, Talebi Mehdi, Baybordi Elahe, Dadpour Mohammad Reza, Salehi Roya, Mehrmohammadi Mohammad
Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz 5154853431, Iran.
Proteomics Research Centre, Tabriz University of Medical Sciences, Tabriz 5154853431, Iran.
ACS Omega. 2020 Sep 17;5(38):24628-24638. doi: 10.1021/acsomega.0c03215. eCollection 2020 Sep 29.
This study aims to engineer a new type of ultrahigh quantum yield carbon dots (CDs) from methotrexate (MTX-CDs) with self-targeting, imaging, and therapeutic effects on MDA-MB 231 breast cancer cells. CDs were synthesized via a straightforward thermal method using a methotrexate (MTX) drug source. The physicochemical characteristics of the prepared MTX-CDs were studied using Fourier transform infrared (FT-IR) spectroscopy, transmission electron microscopy (TEM), dynamic light scattering (DLS), X-ray powder diffraction (XRD), and X-ray photoelectron spectroscopy (XPS). TEM and DLS revealed which MTX-CDs have homogeneous spherical morphology with a smaller average size of 5.4 ± 2.2 nm, polydispersity index (PDI) of 0.533, and positive surface charge of around +3.93 mV. Results of FT-IR spectroscopy and high-resolution XPS indicated the presence of residues of MTX on CDs. Therefore, the synthesized MTX-CDs could be targeted and be taken up by FR-positive cell lines without the aid of additional targeting molecules. In vitro epifluorescence images demonstrated high-contrast cytoplasm biodistribution of MTX-CDs after 2 h of treatment. A much stronger fluorescent signal was detected in MDA-MB 231 compared to MCF 7, indicating their ability to precisely target FR. The highest cytotoxic and apoptotic effects were observed in MTX-CDs compared to free MTX obtained by the MTT assay, cell cycle arrest, and annexin V-FITC apoptosis techniques. Results revealed that the novel engineered MTX-CDs were capable of inducing apoptosis (70.2% apoptosis) at a lower concentration (3.2 μM) compared to free MTX, which was proved by annexin V and cell cycle. This work highlights the potential application of CDs for constructing an intelligent nanomedicine with integration of diagnostic, targeting, and therapeutic functions.
本研究旨在利用甲氨蝶呤制备一种新型的具有超高量子产率的碳点(MTX-CDs),其对MDA-MB 231乳腺癌细胞具有自靶向、成像及治疗作用。通过使用甲氨蝶呤(MTX)药物源,采用简单的热法合成了碳点。利用傅里叶变换红外(FT-IR)光谱、透射电子显微镜(TEM)、动态光散射(DLS)、X射线粉末衍射(XRD)和X射线光电子能谱(XPS)研究了所制备的MTX-CDs的物理化学特性。TEM和DLS显示,MTX-CDs具有均匀的球形形态,平均粒径较小,为5.4±2.2 nm,多分散指数(PDI)为0.533,表面正电荷约为+3.93 mV。FT-IR光谱和高分辨率XPS结果表明碳点上存在MTX残基。因此,合成的MTX-CDs无需额外的靶向分子即可被FR阳性细胞系靶向并摄取。体外落射荧光图像显示,处理2小时后MTX-CDs在细胞质中的生物分布具有高对比度。与MCF 7相比,在MDA-MB 231中检测到更强的荧光信号,表明它们能够精确靶向FR。与通过MTT法、细胞周期阻滞和膜联蛋白V-FITC凋亡技术获得的游离MTX相比,MTX-CDs具有最高的细胞毒性和凋亡作用。结果显示,与游离MTX相比,新型工程化MTX-CDs能够在较低浓度(3.2 μM)下诱导凋亡(凋亡率为70.2%),这通过膜联蛋白V和细胞周期得到了证实。这项工作突出了碳点在构建具有诊断、靶向和治疗功能一体化的智能纳米药物方面的潜在应用。